By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cynapsus Therapeutics 

828 Richmond Street West

Toronto  Ontario  M6J 1C9  Canada
Phone: 416-703-2449 Fax: 416-703-8752


SEARCH JOBS

Cynapsus is a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of “off” motor symptoms of Parkinson’s disease. Cynapsus’ drug candidate, APL-130277, is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from “off” episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a New Drug Application (“NDA”) expected to be submitted in 2016. The company is located in Toronto, ON.


Key Statistics


Email: info@cynapsus.ca
Ownership: Public

Web Site: Cynapsus Therapeutics
Employees: 10
Symbol: CYNAF
 



Industry
Pharmaceutical






Company News
Cynapsus Therapeutics (CYNAF) Announces Uplisting To The Toronto Stock Exchange’s Senior Equity Market 11/26/2014 8:42:45 AM
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014 6:01:01 AM
Cynapsus Therapeutics (CYNAF) Announces Hiring Of New Chief Scientific Officer And EVP, CMC 10/7/2014 3:24:06 PM
Cynapsus Therapeutics Awarded Second Grant From The Michael J. Fox Foundation For Parkinson's Research 7/8/2014 10:24:34 AM
Cynapsus Therapeutics Announces No Buccal Mucosal Irritation In FDA Registration Study Of APL-130277 For Parkinson’s Disease 5/14/2014 11:55:20 AM
Cynapsus Therapeutics Announces Positive Results Of CTH-104 Clinical Study Of APL-130277 For Parkinson's Disease 4/24/2014 10:46:06 AM
Cynapsus Therapeutics Completes $25,000,000 Short Form Prospectus Offering 4/23/2014 1:52:29 PM
Cynapsus Therapeutics Reports 2013 Financial Results And Highlights Key Developments 4/2/2014 10:51:49 AM
Cynapsus Therapeutics Announces Interim Summary Results Of Human Healthy Volunteer Single 25mg Study For APL-130277 4/2/2014 10:48:21 AM
LifeSci Advisors Initiates Coverage Of Cynapsus Therapeutics 2/10/2014 9:21:19 AM
12
//-->